Antibodies against interleukin-1 β

US7964193B2 · kind B2 · utility

Assignee

• Amgen Fremont Inc. · US

Inventors

• Larry Green · San Francisco, US
• Raffaella Faggioni · Pleasanton, US
• Orit Foord · Foster City, US
• Scott L. Klakamp · Russell, US
• Giorgio Senaldi · Thousand Oaks, US
• Amy Schneider · Dublin, US

Key dates

• Filing date: Jun 19, 2009
• Grant date: Jun 21, 2011
• Expiry date: Jun 19, 2029

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/867
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies directed to the antigen IL-1β and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen IL-1β. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.